维力医疗(603309) - 2022 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2022 was ¥300,916,009.24, representing a year-on-year increase of 36.85%[2] - The net profit attributable to shareholders was ¥38,612,671.22, reflecting a significant growth of 70.10% compared to the same period last year[2] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥34,716,162.95, up by 75.15% year-on-year[2] - Basic earnings per share were ¥0.13, an increase of 44.44% year-on-year[2] - Net profit for Q1 2022 reached CNY 41,416,184.78, representing a 66.7% increase from CNY 24,826,527.82 in Q1 2021[18] - Earnings per share for Q1 2022 were CNY 0.13, compared to CNY 0.09 in Q1 2021, reflecting a 44.4% increase[19] Cash Flow - The net cash flow from operating activities reached ¥28,301,006.76, a remarkable increase of 1,081.72% compared to the previous year[2] - In Q1 2022, the company generated cash inflows from operating activities amounting to CNY 327,681,159.86, a 30.8% increase from CNY 250,700,295.51 in Q1 2021[20] - The net cash flow from operating activities for Q1 2022 was CNY 28,301,006.76, significantly up from CNY 2,394,893.02 in the same period last year[20] - Cash inflows from investment activities totaled CNY 205,314,748.68 in Q1 2022, compared to CNY 20,100,803.85 in Q1 2021, marking a substantial increase[21] - The net cash flow from investment activities was negative at CNY -350,894,954.10 in Q1 2022, worsening from CNY -56,540,363.91 in Q1 2021[21] - The company reported cash inflows from financing activities of CNY 62,680,988.54 in Q1 2022, compared to CNY 1,050,000.00 in Q1 2021[21] - The net cash flow from financing activities improved to CNY 57,691,827.75 in Q1 2022, compared to a negative CNY -1,516,178.09 in Q1 2021[21] - The ending balance of cash and cash equivalents was CNY 339,330,654.52 at the end of Q1 2022, up from CNY 106,152,447.48 at the end of Q1 2021[21] - The company experienced a net decrease in cash and cash equivalents of CNY -265,253,439.83 in Q1 2022, compared to CNY -55,701,114.53 in Q1 2021[21] Assets and Liabilities - The total assets at the end of the reporting period were ¥2,187,917,783.34, up by 2.61% from the end of the previous year[3] - The equity attributable to shareholders at the end of the reporting period was ¥1,617,094,106.51, reflecting a 2.45% increase from the previous year[3] - The company's total liabilities as of Q1 2022 amounted to CNY 555,009,190.11, a slight increase from CNY 540,870,556.73 in the previous year[14] - Total equity attributable to shareholders was CNY 1,617,094,106.51 in Q1 2022, up from CNY 1,578,481,435.29 in Q1 2021, indicating a growth of 2.4%[14] - The total current assets were reported at RMB 942,651,432.16, down from RMB 974,541,894.66, indicating a decrease of approximately 3.3%[12] - The company's total liabilities and shareholders' equity are not specified in the provided data, but the asset growth indicates potential for improved financial stability[10] Sales Performance - The company experienced a 22% growth in domestic sales and a 56% increase in international sales compared to the same period last year[5] Research and Development - Research and development expenses for Q1 2022 were CNY 13,117,131.96, an increase from CNY 11,312,222.86 in Q1 2021, showing a growth of 15.9%[16] Non-Recurring Items - Non-recurring gains and losses amounted to ¥3,896,508.27 after tax adjustments[5] Investment Activities - The company received CNY 204,362,523.60 from the recovery of investments in Q1 2022, a significant increase from CNY 20,000,000.00 in Q1 2021[21] - The company paid CNY 514,082,487.25 for investments in Q1 2022, compared to CNY 51,000,000.00 in Q1 2021, indicating a substantial increase in investment activities[21] Future Outlook - The company has not provided specific future guidance or performance outlook in the current report[10] - The company has not disclosed any new product developments or market expansion strategies in the current report[10] - There are no significant mergers or acquisitions reported during the quarter[10]